TherapeuticsMD Announces Estimated Third Quarter 2019 Financial Results
TherapeuticsMD, Inc. (TXMD)
NASDAQ:AMEX Investor Relations:
ir.therapeuticsmd.com
Company Research
Source: Business Wire
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (the “Company”) today announced its estimates of the financial results for the third quarter ended September 30, 2019.For the three months ended September 30, 2019, the Company estimates that its consolidated net revenue from its prescription vitamin business will range from approximately $2.50 million to $2.60 million, compared to consolidated net revenue from its prescription vitamin business of approximately $2.80 million for the three months ended June 30, 2019. For the three months ended September 30, 2019, the Company estimates that its consolidated net revenue from sales of its U.S. Food and Drug Administration approved products IMVEXXY®, BIJUVA®, and ANNOVERA® will range from approximately $5.32 million to $5.70 million, compared to consolidated net revenue from sales of IMVEXXY and BIJUVA of approximately $3.3 million for the three months ended June 30, 2019. Sales of ANNOVERA commenced in August 2019.
Show less
Read more
Impact Snapshot
Event Time:
TXMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXMD alerts
High impacting TherapeuticsMD, Inc. news events
Weekly update
A roundup of the hottest topics
TXMD
News
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
TXMD
Sec Filings
- 10/25/24 - Form ARS
- 10/25/24 - Form DEFA14A
- 10/25/24 - Form DEF
- TXMD's page on the SEC website